Product Description
Lincomycin 250mg Capsules: What the Published Guidance Says
A broad portfolio spanning the WHO Access and Watch groups, supplied with the documentation that stewardship programmes and national tenders require.
Before Lincomycin 250mg Capsules is quoted, we confirm the monograph, the strength on the artwork and the release testing required by your market — the points summarised here.
- WHO's own indication mapping is public — we align to it The WHO Antibiotics Portal lists amoxicillin as first choice for community-acquired pneumonia (mild to moderate), acute otitis media, acute sinusitis, acute pharyngitis and uncomplicated acute malnutrition in children; amoxicillin + clavulanic acid as first choice for severe community-acquired pneumonia in children, hospital-acquired pneumonia, cystitis and cellulitis; and ceftriaxone as first choice for severe acute pyelonephritis. WHO Antibiotics Portal — AWaRe
- Access group — the empirical workhorses The WHO AWaRe classification places amoxicillin, amoxicillin + clavulanic acid, ampicillin, clindamycin, gentamicin, metronidazole, chloramphenicol and doxycycline in the Access group. These are the medicines expected to be available in every functioning health system. WHO AWaRe (Access, Watch, Reserve) classification of antibiotics
- AWaRe is the framework buyers and stewards now work to WHO's AWaRe classification divides antibiotics into Access, Watch and Reserve. Access agents are described as those that should be widely available, affordable and quality-assured to improve access and promote appropriate use. Watch agents carry higher resistance potential and should be prioritised as targets of stewardship programmes and monitoring. WHO Antibiotics Portal — AWaRe
Each point above is reproduced because it has a practical consequence for Lincomycin 250mg Capsules: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Lincomycin 250mg Capsules — Supply Parameters
| Product Name | Lincomycin Capsules 250mg (Lincomycin Hydrochloride 250mg Oral Capsules) |
| Specification | Each capsule contains: Lincomycin Hydrochloride equivalent to Lincomycin 250mg |
| Dosage Form | Oral Hard Gelatin Capsule (for oral administration; swallow whole) |
| Active Ingredient | Lincomycin (as Lincomycin Hydrochloride) |
| Pharmacological Class | Lincosamide Antibiotic (Gram-Positive / Anaerobic Bacterial Protein Synthesis Inhibitor) |
| Route of Administration | Oral administration (swallow whole with a full glass of water). Take on an empty stomach (at least 1 hour before or 2 hours after meals) for optimal absorption. Typically taken 3 to 4 times daily, as directed by a healthcare professional. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Antibacterials — Antibacterials |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Ampicillin 500mg Capsules, Azithromycin 400mg Capsules, Clarithromycin 250mg Capsules, Amoxicillin 500mg Capsules, Norfloxacin 100mg Capsules, Oxytetracycline 250mg Capsules, Ciprofloxacin 500mg Tablets, Amoxicillin Clavulanate 875/125mg Tablets.
Quality Control, Pharmacopoeial Standards & Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Lincomycin 250mg Capsules follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
A typical release panel for this presentation covers:
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
- Testing for packaging integrity and seal testing
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packaging, Labelling & Export
- Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 10, 20, 30, or 100 capsules per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Registration, Dossier & Tender Support
The legal manufacturer named on every document for Lincomycin 250mg Capsules is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
Lincomycin 250mg Capsules is presented here against antibacterials classified in the WHO AWaRe framework. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Frequently Asked Questions
What pack size is available for Lincomycin 250mg Capsules?
Standard commercial packaging for this line is Blister pack (PVC-Alu) or HDPE bottle, typically 10, 20, 30, or 100 capsules per blister pack or bottle. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Lincomycin 250mg Capsules?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Lincomycin 250mg Capsules support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Which of your antibiotics are in the WHO Access group?
Amoxicillin, amoxicillin + clavulanic acid, ampicillin, clindamycin, gentamicin, metronidazole and chloramphenicol are classified in the Access group under the WHO AWaRe classification.
Can you supply sterile injectable antibiotics with endotoxin data?
Yes. Injectable products are supplied with sterility and bacterial endotoxin results included on the batch certificate of analysis, alongside assay and related-substances data.
Related Antibacterials Products
- Ampicillin 500mg Capsules — 500mg
- Azithromycin 400mg Capsules — 400mg
- Clarithromycin 250mg Capsules — 250mg
- Amoxicillin 500mg Capsules — 500mg
- Norfloxacin 100mg Capsules — 100mg
- Oxytetracycline 250mg Capsules — 250mg
Browse the full Antibacterials range; all Capsules; the complete product catalogue.
Request a Quotation for Lincomycin 250mg Capsules
Tell us the monograph, pack size and quantity required for Lincomycin 250mg Capsules 250mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
